Cerebellar ataxia-hypogonadism syndrome

Cerebellar ataxia-hypogonadism syndrome, also known as Gordon Holmes syndrome or cerebellar ataxia with hypogonadotropic hypogonadism, is a rare neurodegenerative disorder characterized by the combination of progressive cerebellar ataxia and hypogonadotropic hypogonadism. The condition affects both the central nervous system and the reproductive endocrine system. Cerebellar degeneration leads to progressive difficulties with coordination, balance, gait, and fine motor movements, while hypogonadotropic hypogonadism results from insufficient production of gonadotropin-releasing hormone (GnRH) or gonadotropins (LH and FSH), leading to delayed or absent puberty, infertility, and underdeveloped secondary sexual characteristics. The neurological features typically include progressive gait and limb ataxia, dysarthria (slurred speech), nystagmus, and in some cases cognitive decline or dementia. The hypogonadism may manifest as delayed puberty, amenorrhea in females, or small testes and reduced virilization in males. Additional features reported in some patients include choreoathetosis and other movement abnormalities. Several genetic causes have been identified, including mutations in the RNF216 gene, OTUD4 gene, STUB1 gene, and PNPLA6 gene, among others. These genes are involved in protein ubiquitination pathways or lipid metabolism, highlighting the molecular complexity of this syndrome. There is currently no cure for cerebellar ataxia-hypogonadism syndrome. Treatment is symptomatic and supportive. Hormone replacement therapy can address the hypogonadism, promoting development of secondary sexual characteristics and potentially improving bone health. Physical therapy, occupational therapy, and speech therapy may help manage the progressive neurological symptoms. Genetic counseling is recommended for affected families.

Common questions about Cerebellar ataxia-hypogonadism syndrome